Research on the efficacy of eicosapentaenoic acid (EPA) on coronary plaque formation in patients undergoing percutaneous coronary intervention

INTERVENTION: Intervention 1: Atrovastatin (Lipitor: 5 mg, 10 mg), pitavastatin (Livalo: 1 mg, 2 mg) or rosuvastatin (Crestol: 2.5 mg, 5 mg) Combined application of high‐purity EPA preparation (Epadel 1,800 mg) with intervention 1. CONDITION: Patients underdoing percutaneous coronary intervention complicated with dyslipidemia. PRIMARY OUTCOME: Evaluation of changes in plaque formation before and after medication by integrated backscatter intravascular ultrasound (IB‐IVUS). SECONDARY OUTCOME: 1.Changes in blood inflammation and coagulation markers; hs‐CRP; IL‐6; TNF‐alpha; IP‐10; MMP‐3; MMP‐9; PTX3; Heparin cofactor 2; 2.Blood EPA/AA ratio; 3.Vascular endothelial function (flow‐mediated dilatation; FMD) INCLUSION CRITERIA: 1) Patients in which stenosis is found to exceed 75% in 1‐2 vessels, prompting implantation of a bare‐metal stent (BMS) by percutaneous coronary intervention (PCI). 2) Patients with LDL cholesterol 160 mg/dl or above, patients having taken strong statin, or mild statin with LDL cholesterol 100 mg/dl or above.